◼ Archived
Business
Merck KGaA buys Silence in $1.3B deal after siRNA drug's phase 2 blood cancer win
Merck KGaA acquires Silence Therapeutics for $1.3 billion following a phase 2 trial win for an siRNA drug.
4 trends tracked about this subject — the full history, oldest to newest below.
Merck KGaA acquires Silence Therapeutics for $1.3 billion following a phase 2 trial win for an siRNA drug.
2 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
5 news sources are covering this Business story right now — PULSE is tracking how fast it spreads.
Silence Therapeutics advances its gene-silencing drug divesiran toward Phase III following mid-stage trial success in polycythemia vera.